Aethlon Medical (NasdaqCM:AEMD) - Share price, News & Analysis

AEMD fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

AEMD Stock Overview

Aethlon Medical, Inc., a medical technology company, focuses on developing products to diagnose and treat life and organ threatening diseases in the United States.

Risk Analysis

Earnings are forecast to decline by an average of 11.8% per year for the next 3 years

Highly volatile share price over the past 3 months

Makes less than USD$1m in revenue ($162K)

Currently unprofitable and not forecast to become profitable over the next 3 years

+ 2 more risks

Aethlon Medical Competitors

Precision Optics Corporation

OTCPK:PEYE

US$33.8m

Biomerica

NasdaqCM:BMRA

US$39.7m

Delcath Systems

NasdaqCM:DCTH

US$41.3m

NeuroOne Medical Technologies

NasdaqCM:NMTC

US$29.8m

Price History & Performance

Summary of all time highs, changes and price drops for Aethlon Medical
Historical stock prices
Current Share Price	US$1.36
52 Week High	US$5.99
52 Week Low	US$0.88
Beta	0.78
1 Month Change	33.33%
3 Month Change	32.26%
1 Year Change	-64.58%
3 Year Change	-67.62%
5 Year Change	-94.07%
Change since IPO	-99.98%

Recent News & Updates

Aug 02

We're Keeping An Eye On Aethlon Medical's (NASDAQ:AEMD) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

Jul 11

FDA approves protocol change in Aethlon's trial of its purifier to treat severe COVID

Aethlon Medical (NASDAQ:AEMD) on Monday said the U.S. FDA had approved a change in the protocol of the company's ongoing trial evaluating its blood filtration system to treat patients with severe COVID-19. AEMD said the change in protocol eliminates the inclusion criteria that patients must have a dialysis catheter in place and have tolerated dialysis at the time of screening. The trial is currently evaluating the safety and efficacy of AEMD's Aethlon Hemopurifier product. The trial is designed to enroll up to 40 severe COVID-19 patients. "We anticipate that this protocol amendment will enable us to enroll patients at an increased rate now that dialysis treatment is no longer a study requirement", said AEMD CEO Charles Fisher, Jr.

Shareholder Returns

	AEMD	US Medical Equipment	US Market
7D	-18.6%	1.9%	3.2%
1Y	-64.6%	-19.1%	-10.1%

Return vs Industry: AEMD underperformed the US Medical Equipment industry which returned -20.3% over the past year.

Return vs Market: AEMD underperformed the US Market which returned -11.7% over the past year.

Price Volatility

Is AEMD's price volatile compared to industry and market?
AEMD volatility
AEMD Average Weekly Movement	24.2%
Medical Equipment Industry Average Movement	9.4%
Market Average Movement	7.7%
10% most volatile stocks in US Market	16.9%
10% least volatile stocks in US Market	3.2%

Stable Share Price: AEMD is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 24% a week.

Volatility Over Time: AEMD's weekly volatility has increased from 15% to 24% over the past year.

About the Company

Founded	Employees	CEO	Website
1999	14	Chuck Fisher	https://www.aethlonmedical.com

Aethlon Medical, Inc., a medical technology company, focuses on developing products to diagnose and treat life and organ threatening diseases in the United States. The company develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system, including removal of COVID-19 virus, associated variants, and related exosomes. Aethlon Medical, Inc. has a collaboration with the University of Pittsburgh Medical Center Hillman Cancer Center for studies related to head and neck cancer.

Aethlon Medical Fundamentals Summary

How do Aethlon Medical's earnings and revenue compare to its market cap?
AEMD fundamental statistics
Market Cap	US$31.14m
Earnings (TTM)	-US$11.22m
Revenue (TTM)	US$162.20k

192.1x

P/S Ratio

-2.8x

P/E Ratio

Is AEMD overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
AEMD income statement (TTM)
Revenue	US$162.20k
Cost of Revenue	US$0
Gross Profit	US$162.20k
Other Expenses	US$11.39m
Earnings	-US$11.22m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)	-0.49
Gross Margin	100.00%
Net Profit Margin	-6,920.18%
Debt/Equity Ratio	0%

How did AEMD perform over the long term?

See historical performance and comparison

We’ve recently updated our valuation analysis.

Valuation

Is AEMD undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for AEMD?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for AEMD. This is calculated by dividing AEMD's market cap by their current preferred multiple.
What is AEMD's n/a Ratio?
n/a Ratio	0x
n/a	n/a
Market Cap	US$31.14m

AEMD key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	103.5x
Enterprise Value/EBITDA	-1.5x
PEG Ratio	n/a

Price to Book Ratio vs Peers

How does AEMD's PB Ratio compare to its peers?

AEMD PB Ratio vs Peers

The above table shows the PB ratio for AEMD vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	PB	Estimated Growth	Market Cap
Peer Average	-0.9x
PEYE Precision Optics Corporation	4x	n/a	US$33.8m
BMRA Biomerica	4.1x	n/a	US$39.7m
DCTH Delcath Systems	n/a	61.1%	US$41.3m
NMTC NeuroOne Medical Technologies	2.8x	-7.5%	US$29.8m
AEMD Aethlon Medical	2.1x	-11.8%	US$31.1m

Price-To-Book vs Peers: AEMD is expensive based on its Price-To-Book Ratio (2.1x) compared to the peer average (-0.9x).

Price to Earnings Ratio vs Industry

How does AEMD's PE Ratio compare vs other companies in the US Medical Equipment Industry?

Price-To-Book vs Industry: AEMD is good value based on its Price-To-Book Ratio (2.1x) compared to the US Medical Equipment industry average (2.8x)

Price to Book Ratio vs Fair Ratio

What is AEMD's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

AEMD PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio	2.1x
Fair PB Ratio	n/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate AEMD's Price-To-Book Fair Ratio for valuation analysis.

Share Price vs Fair Value

What is the Fair Price of AEMD when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate AEMD's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate AEMD's fair value for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Future Growth

How is Aethlon Medical forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

-11.8%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: AEMD is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: AEMD is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: AEMD is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: AEMD's revenue is expected to decline over the next 3 years (-50.8% per year).

High Growth Revenue: AEMD's revenue is forecast to decline over the next 3 years (-50.8% per year).

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if AEMD's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Past Performance

How has Aethlon Medical performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

-12.0%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: AEMD is currently unprofitable.

Growing Profit Margin: AEMD is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: AEMD is unprofitable, and losses have increased over the past 5 years at a rate of 12% per year.

Accelerating Growth: Unable to compare AEMD's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: AEMD is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (2.5%).

Return on Equity

High ROE: AEMD has a negative Return on Equity (-75.26%), as it is currently unprofitable.

Discover strong past performing companies

Financial Health

How is Aethlon Medical's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: AEMD's short term assets ($15.9M) exceed its short term liabilities ($1.6M).

Long Term Liabilities: AEMD's short term assets ($15.9M) exceed its long term liabilities ($567.3K).

Debt to Equity History and Analysis

Debt Level: AEMD is debt free.

Reducing Debt: AEMD currently has no debt however we can't compare to 5 years ago as we have no data for that period.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: AEMD has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: AEMD has sufficient cash runway for 1.2 years if free cash flow continues to reduce at historical rates of 18.7% each year.

Discover healthy companies

Dividend

What is Aethlon Medical current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Cash Flow Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate AEMD's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate AEMD's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if AEMD's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if AEMD's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as AEMD has not reported any payouts.

Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

1.8yrs

Average management tenure

CEO

Chuck Fisher (75 yo)

1.83yrs

Tenure

US$2,477,896

Compensation

Dr. Charles J. Fisher, Jr., also known as Chuck, M.D. has been Chief Executive Officer of Aethlon Medical, Inc. since October 30, 2020. He serves as the Chief Executive Officer of Margaux Biologics, Inc. s...

CEO Compensation Analysis

Compensation vs Market: Chuck's total compensation ($USD2.48M) is above average for companies of similar size in the US market ($USD763.69K).

Compensation vs Earnings: Chuck's compensation has increased whilst the company is unprofitable.

Leadership Team

Experienced Management: AEMD's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.

Board Members

Experienced Board: AEMD's board of directors are considered experienced (4.8 years average tenure).

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 48.8%.

Data	Last Updated (UTC time)
Company Analysis	2022/08/12 00:00
End of Day Share Price	2022/08/12 00:00
Earnings	2022/06/30
Annual Earnings	2022/03/31